Leadership · Enterprise

Turn bioprocess spend into an asset.

Your bioprocess teams run program after program, year after year. With Invert, the insights generated from each turn into an asset that pays off every time a new program starts. Our tools enforce data quality standards, and learn the context around your experimental spend, so future programs won’t have to reproduce work.

Challenge

Institutional knowledge isn’t codified

When a senior scientist leaves, the reasoning behind parameter choices leaves with them. When PD hands off to MSAT, years of DOE context compress to a one-page summary. When a site reorganizes, last year’s data becomes unsearchable. Every attrition event rewinds the clock.

Scientific cul-de-sacs are expensive

The experience of spending months and millions pursuing an ultimately unsuccessful process strategy is a common one. Demanding batch schedules lead to insufficient data analysis and missed opportunities to course correct.

Bioprocess teams are wary of digitalization

Bioprocess teams have historically been underserved by software. LIMS and ELN don’t quite fit their workflows, and internal projects tend to fail. This leads to digitalization fatigue which prevents your teams from adopting modern technology.

Every IT project is a five-year bet

Homegrown infrastructure consumes roadmap capacity year after year. Off-the-shelf tools from 2018 solve 2018’s problems. The platform you buy today has to work with the stack you have, the AI you’ll adopt next year, and the programs you haven’t started yet.

How Invert helps

Case study · Top 10 biopharma

Operationalized a $2M+ digital twin by closing the Ambr250 data gap.

<1 mo
to go live
$2M+
investment unlocked
Real-time
data feed
Read the full case study

The data is the asset. Build it on purpose.

Book a working session with our team. We'll walk through the architecture, the adoption model, and what the first quarter of outcomes looks like for a program like yours.

Talk to usRead the case studies